For individuals carrying BRCA1 or BRCA2 mutations and diagnosed with HER2- breast cancer, treatment with PARP inhibitors such as olaparib and talazoparib may be considered [55, 56]. This evidence concerns the gene BRCA2 and breast carcinoma.